BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
– BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023
– Preliminary findings and study results will be presented in an oral presentation and posters at the Muscular Dystrophy Association (MDA) 2023 Annual Meeting
– Additionally, BridgeBio will host an investor call with Jeffrey Rosenfeld, M.D., Ph.D., a specialist in neuromuscular medicine and professor of neurology at Loma Linda University School of Medicine on Tuesday, March 21 at 8:30 am ET to discuss the findings on the bioassay, the updated Phase 2 study results and the preliminary Phase 3 study design
PALO ALTO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that preliminary data on the Company’s muscle tissue-based bioassay measuring glycosylated ⍺DG in LGMD2I patients will be featured in an oral presentation and posters at the MDA 2023 Annual Meeting, taking place in Dallas, Texas on March 19 – 22, 2023. BridgeBio will host an investor call with Jeffrey Rosenfeld, M.D., Ph.D., a specialist in neuromuscular medicine and professor of neurology at Loma Linda University School of Medicine on Tuesday, March 21 at 8:30 am ET to discuss the results shared at the meeting.
BridgeBio was selected to share an oral presentation and posters on its ongoing Phase 2 trial with 15-month results, including the preliminary design of its pivotal Phase 3 study in patients with LGMD2I, which is expected to launch in mid-2023.
Oral Presentation and Poster Details:
Preliminary Results from MLB-01-003: An Open Label Phase 2
Study of BBP-418 in Patients with Limb-girdle Muscular
Dystrophy Type 2I
Date/ Time: Monday, March 20 at 2:30 – 3:00 pm
CT
Presenter: Douglas Sproule, M.D., M.Sc., chief
medical officer of ML Bio Solutions, a BridgeBio affiliate that
is focused on developing BBP-418 for LGMD2I
Location: Coronado A; Hilton Anatole, Dallas,
TX
Session: Ultra-Rare Track
Longitudinal Measurement Using a Novel Western Blot Assay of
Glycosylation of Alpha- dystroglycan in Patients with
Limb-girdle Muscular Dystrophy Type 2I/R9 FKRP-related:
Preliminary Results from MLB-01-001
Date/ Time: Monday, March 20 and Tuesday, March
21 at 6:00 – 8:00 pm CT
Location: Trinity Exhibit Hall; Hilton Anatole,
Dallas, TX
Poster Number: #140
Preliminary Results from MLB-01-003: An Open Label Phase 2
Study of BBP-418 in Patients with Limb-girdle Muscular
Dystrophy Type 2I
Date/ Time: Monday, March 20 and Tuesday, March
21, at 6:00 – 8:00 pm CT
Location: Trinity Exhibit Hall; Hilton Anatole,
Dallas, TX
Poster Number: #139
Webcast Information
BridgeBio will host an investor call and simultaneous webcast to
discuss the LGMD2I program updates shared at MDA on Tuesday,
March 21 at 8:30 am ET. A link to the webcast may be accessed
from the event calendar page of BridgeBio’s website at
https://investor.bridgebiodev.wpengine.com/. A replay of the conference call and webcast will be archived
on the Company’s website and will be available for at least 30
days following the event.
About Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
LGMD2I is a monogenic autosomal recessive disease caused by
partial loss of function mutations in the FKRP gene, and FKRP
mutations impair glycosylation of αDG, a protein associated with
stabilizing muscle cells. Clinical manifestations typically
present as a skeletal myopathy affecting the lower and then
upper limbs, which is commonly later accompanied by respiratory
muscle and cardiac muscle involvement. Patients who harbor a
homozygous genotype typically develop disease manifestations
during late childhood with progression to loss of independent
ambulation (25%), assisted ventilation (5%), and cardiomyopathy
(10%) in adulthood. Cardiomyopathy is progressive, with an
annual loss of 0.4% of left ventricular ejection fraction
(LVEF). Patients with heterozygous genotypes have an earlier
childhood onset with a more severe clinical course, rapid loss
of mobility by 20 years of age, more frequent cardiac
involvement (25%), and eventual respiratory failure by 30 years
of age in nearly all cases.
About BridgeBio Pharma, Inc.
BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of development programs ranges from early
science to advanced clinical trials. BridgeBio was founded in
2015 and its team of experienced drug discoverers, developers,
and innovators are committed to applying advances in genetic
medicine to help patients as quickly as possible. For more
information visit bridgebiodev.wpengine.com and follow us on LinkedIn and Twitter.
BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements.
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), which are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section
27A of the Securities Act and Section 21E of the Exchange
Act. These forward-looking statements, including statements
relating to the clinical and therapeutic potential of the
Company’s programs and product candidates, including our
clinical development program for BBP-418 for the treatment of
LGMD2I, the availability of data from our Phase 2 clinical trial
of BBP-418 and timing of this event, the progress of the
Company’s ongoing and planned clinical trials of BBP-418 for the
treatment of LGMD2I, including the expectation to initiate a
Phase 3 clinical trial in mid-2023, the typical clinical
manifestations of LGMD2I and progression to loss of independent
ambulation, assisted ventilation and cardiomyopathy, the impact
on patients with heterozygous genotypes, and the timing and
success of BridgeBio’s clinical trials and development pipeline,
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions,
expectations, strategies and prospects as reflected in or
suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations
or strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a number of
risks, uncertainties and assumptions, including, but not limited
to, our ability to continue and complete our ongoing and planned
clinical trials of BBP-418 for the treatment of LGMD2I, initial
and ongoing data from our clinical trials not being indicative
of final data , the design and success of ongoing and planned
clinical trials, the U.S. Food and Drug Administration (FDA) or
other regulatory agencies not agreeing with our regulatory
approval strategies, components of our filings, such as clinical
trial designs, conduct and methodologies, or the sufficiency of
data submitted, our ability to advance our clinical trials and
development pipeline, as well as those risks set forth in the
Risk Factors section of BridgeBio’s Annual Report on Form 10-K
for the year ended December 31, 2022, and BridgeBio’s other SEC
filings. Moreover, BridgeBio operates in a very competitive and
rapidly changing environment in which new risks emerge from time
to time. These forward-looking statements are based upon the
current expectations and beliefs of our management as of the
date of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ
materially from those described in the forward-looking
statements. Except as required by applicable law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
BridgeBio Media Contact:
Vikram Bali
[email protected]
(650)-789-8220